Giuseppe Ciaramella - Jun 28, 2021 Form 4 Insider Report for Beam Therapeutics Inc. (BEAM)

Role
President & CSO
Signature
By: /s/ Christine Bellon, Attorney-in-fact,
Stock symbol
BEAM
Transactions as of
Jun 28, 2021
Transactions value $
-$7,099,505
Form type
4
Date filed
6/30/2021, 06:00 PM
Previous filing
Sep 21, 2021
Next filing
Sep 21, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BEAM Common Stock Options Exercise $1.34M +78.6K +175.55% $17.00 123K Jun 28, 2021 Direct F1
transaction BEAM Common Stock Sale -$250K -2.41K -1.95% $103.83 121K Jun 28, 2021 Direct F2, F3
transaction BEAM Common Stock Sale -$570K -5.46K -4.52% $104.40 115K Jun 28, 2021 Direct F2, F4
transaction BEAM Common Stock Sale -$743K -7.04K -6.1% $105.52 108K Jun 28, 2021 Direct F2, F5
transaction BEAM Common Stock Sale -$1.11M -10.4K -9.63% $106.35 98K Jun 28, 2021 Direct F2, F6
transaction BEAM Common Stock Sale -$1.16M -10.8K -11.05% $107.30 87.2K Jun 28, 2021 Direct F2, F7
transaction BEAM Common Stock Sale -$3.28M -30.4K -34.84% $108.11 56.8K Jun 28, 2021 Direct F2, F8
transaction BEAM Common Stock Sale -$1.08M -9.86K -17.36% $109.32 46.9K Jun 28, 2021 Direct F2, F9
transaction BEAM Common Stock Sale -$239K -2.17K -4.63% $110.00 44.8K Jun 28, 2021 Direct F2, F10

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BEAM Stock Option (Right to Buy) Options Exercise $0 -78.6K -15.38% $0.00 432K Jun 28, 2021 Common Stock 78.6K $17.00 Direct F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option exercise reported in this Form 4 was effected pursuant to a 10b5-1 trading plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.74 to $103.97, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.04 to $104.96, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.01 to $105.98, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.00 to $106.97, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.00 to $107.99, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to $108.90, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.00 to $109.95, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.01, inclusive.
F11 25% of the shares subject to the stock option shall vest on the first anniversary of the vesting commencement date, February 5, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.